Putting quality of life back within reach.
Putting quality of life back within reach.
Founder & Chairman of Adventus Ventures Corp, medical technology incubator and entrepreneur with strong background with both start-up and large established organizations (Johnson & Johnson, St. Jude Medical).
Shawn has held various leadership position; CEO, senior executive, boardmember, and co-founded multiple medical device companies with several successful exists: EP Dynamics, Lavita Technologies, Renal Dynamics, Vessix Vascular, Ellipse Technologies, & Savona Therapeutics, Oncogenics Guidance Systems.
Randy Werneth is a seasoned executive with 25 years of experience in both small entrepreneurial and Fortune 500 corporations in the medical device industry.
Mr. Werneth is CEO of Maxwell Biomedical, inc developing the next generation wireless remote cardiac pacing and monitoring implantable device.
Mr. Werneth is partner at Evolve Medtech Partners, a technology development company.
Previously, Mr. Werneth successfully started several other venture backed companies including Acutus Medical, Securus Medical, Ablation Frontiers, CryoTherapeutics.
Mr. Werneth previously held senior level positions at Medtronic, Micro Therapeutics and Edwards Lifesciences where he engineered and/or managed the design & development of numerous medical technologies and clinical procedures in the fields of stents, neuro-embolic materials, vulnerable plaque and electrophysiology.
He also sits on the board of several venture funded medical device companies in the US and Europe.
Mr. Werneth holds a B.S. degree in Engineering from Arizona State University (ASU) and a Masters in Science from University of California at Los Angeles (UCLA). He has more than 70 issued U.S. Patents in various medical technology fields.
Dan has over 25 years of experience building healthcare technology companies.
Dan is currently the President and CFO of Axonics Modulation Technologies, a medical device company treating overactive bladder. Previously COO & CFO of Vessix Vascular and General Manager responsible for post-acquisition integration after the acquisition by Boston Scientific.
Shinya has the 25-year experience in medical device business. He invested in several Venture companies who develop various new medical devices with hands on operations.
Shinya is currently CEO & President of Neuroceuticals, Inc, privately held company supporting overseas start-up medical device company to enter into Japanese market by investing, and setting up marketing strategy in Japan including obtaining government approval (PMDA approval)
Roy is a member of the Boards of Directors of VytronUS, EPIX Therapeutics, and BioSig Technologies, medical device start-ups developing technologies for treating atrial fibrillation, a cardiac arrhythmia.
He has also served on the boards of Volcano Corporation, a company that develops intravascular ultrasound that aid in the diagnosis and treatment of vascular and structural heart disease, TomoTherapy Incorporated, an advanced radiation therapy company that markets systems for the treatment of a wide range of cancer types, and Coherex, an atrial appendage closure device company.
Prior to his retirement, Roy was the Worldwide President of Biosense Webster, a Johnson & Johnson Company, from March, 2004 until his retirement in September, 2008. Biosense Webster is the market and technology leader in the field of electrophysiology, a subspecialty of cardiology dedicated to the diagnosis and treatment of heart rhythm disorders
James is a physician, patent attorney, and partner at FisherBroyles, where he practices patent litigation and prosecution in the areas of medical devices, biotechnology, software, and pharmaceuticals. He is a cofounder of Highpoint Therapeutics, an oncology startup focused on killing cancer stem cells with nanoencapsulated salinomycin and other agents.
A graduate of the University of Southern California (USC) School of Medicine, James received residency training in internal medicine and in radiology at the Massachusetts General Hospital and Harvard Medical School, where he was awarded a fellowship in neuroradiology. He completed coursework in the Master of Science in Electrical Engineering program at USC, with an emphasis in signal and image processing. He is a member of the American Society for Clinical Nutrition with a research interest in Alzheimer’s disease and other neurodegenerative diseases.
James is recommended in Chambers USA and The Legal 500 United States in the area of life sciences and named a leading patent professional in California by IAM Patent 1000 – The World’s Leading Patent Practitioners for both patent litigation and prosecution, and a Top 25 Portfolio Manager by the Daily Journal. He has served on the scientific board of advisors for several life science companies.
Mahmood received his medical degree from the University of Southern California and completed his residency training at UCLA where he served as the Chief Resident. He has had two subspecialty fellowship trainings at Stanford University and UCLA. He has been on the academic faculties of UCLA and Stanford University Medical Schools and is now the Director of Department of Clnical Trials at St Joseph Heart & Vascular Center.
To date, he has authored or co-authored over 300 scientific publications, abstracts, and book chapters and has been the recipient of many honors and awards from multiple professional medical societies. He has been the recipient of several industry, institutional and federal grants and has given over 450 invited lectures in National & International scientific meetings.
Dr. Razavi has served as the Editor and on the Editorial Boards of several scientific journals. His scientific work has been featured in over 100 national & international radio, television, and press news articles and programs.
Dr. Razavi is the co-founder of four medical device companies with a total exit valuation of over $600M including Trivascular and Neuravi and has served on the Board of Directors and the Scientific and Strategic Advisory Boards of over 40 device and biotechnology companies.
Dr. Wang is seasoned executive with over 20 years medical device industry experience with successful business execution and exits.
Dr. wang currently is chairman of the board of HeMo Bioengineering Limited, medical device company established in 2017 primarily focused on neurovascular intervention currently in China with two operating institutions, Weihai R&D and production and Beijing marketing and sales headquarters.
Prior to this. Dr. Wang was CEO of Biosensors International responsible for significant growth and strategic direction leading to the acquisition of several successful companies.
Prior to joining Biosensors in 2001, Dr. Wang had worked for Johnson & Johnson (Cordis) and Guidant Corporation.
Dr. Wang was granted more than 20 US and European patents in medical devices and technology and has published more than 30 scientific papers on polymer materials and processing, according to a Biosensors International Group report.
Dr. Wang received his doctorate in polymer science from Case Western Reserve University, Cleveland.
Mr. Shigeru Yasue is a seasoned investment executive with broad business development and execution experience leading to multiple successful exits.
Shigeru is currently board of Medical Development Support 1 Limited Partnership with over 20 years of VC investment experience with Mitsubishi UFJ Capital.
Shigeru has been involved with multiple successful exits with both Japanese and U.S. companies including Five Prime Therapeutics, Inc.(FPRX), Opko Health ,Inc.(OPK), Affymax,Inc.(AFFY), MacroGenics Inc. (MGNX), KaloBios Pharmaceuticals,Inc (KBIO), iPierian Inc.,(Acquired by Bristol Myers Squibb), Solasia Pharmaceuticals ( Tokyo Stock Exchange, Mothers), SanBio (TSE, Mothers), StemRim (TSE ,Mothers), Modaris (TSE ,Mothers).
Shigeru was previous board member of TMS,Co.,Ltd.,developing a novel acute stroke agent and was acquired by Biogen in June 2021.
Professor of Neurology, Director, Movement Disorders Program, University of California, Irvine 1999-2020; Section Lead, Neurology, CHRISTUS-St.
Vincent Regional Medical Center, Santa Fe, NM 2020-present.
Nick is seasoned and accomplished technical leader with over 18 years of design & development experience.
Prior to joining Allevion Therapeutics, Nick was the director of technology and innovation at PKG User Interface Inc, responsible for all aspects of system design for medical, aviation, and industrial customers. Nick holds a Master of Science in Engineering from Boise State University.